Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2812-2826

  Mirandola, Leonardo ^a,b   Figueroa, Jose A ^a,c   Phan, Tam T ^a   Grizzi, Fabio ^d   Kim, Minji ^a   Rahman, Rakhshanda Layeequr ^e   Jenkins, Marjorie R ^a,b   Cobos, Everardo ^a,b,c   Jumper, Cynthia ^f   Alalawi, Raed ^f   Chiriva Internati, Maurizio ^a,b,c  

^a TEXAS TECH UNIVERSITY   (United States)

^b Center for Women's Health and Gender Based Medicine   (United States)

^c Kiromic Inc   (United States)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Cancer testis antigens; Lung cancer

Indexed keywords

A KINASE ANCHOR PROTEIN 4; CANCER ANTIBODY; PITUITARY TUMOR TRANSFORMING GENE 1 PROTEIN; SPERM PROTEIN 17; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AKAP4 PROTEIN, HUMAN; AUTOANTIBODY; CARRIER PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; MEMBRANE ANTIGEN; MESSENGER RNA; PITUITARY TUMOR-TRANSFORMING PROTEIN 1, HUMAN; SECURIN; SPA17 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; LARGE CELL LUNG CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; TUMOR IMMUNITY; UPREGULATION; VERY ELDERLY; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; COCULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

A KINASE ANCHOR PROTEINS; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; SECURIN; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 84923296203     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2802     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
2. Mellman I, Coukos G and Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-489.
3. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E and Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. The Prostate. 2012; 72(1):12-23.
4. Caballero OL and Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer science. 2009; 100(11):2014-2021.
5. Mirandola LMJC, Cobos E, Bernardini G, Jenkins MR, Kast WM and Chiriva-Internati M. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. International reviews of immunology. 2011; 30(2-3):127- 137.
6. Mathieu MG, Miles AK, Li G, McArdle SE and Rees RC. Cancer/testis antigens for therapeutic use. Journal of BUON: official journal of the Balkan Union of Oncology. 2009; 14 Suppl 1:S97-102.
7. Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, Gaykalova DA, Sun W, Sidransky D, Ha PK and Califano JA. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(13):4267-4276.
8. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park do Y and Sol MY. Expression of cancertestis antigens MAGE-A3/6 and NY-ESO-1 in non-smallcell lung carcinomas and their relationship with immune cell infiltration. Lung. 2009; 187(6):401-411.
9. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA and Schrump DS. Inhibition of histone lysine methylation enhances cancertestis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer research. 2011; 71(12):4192-4204.
10. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM and Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. Journal of immunotherapy (Hagerstown, Md: 1997). 2011; 34(6):490-499.
11. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E and Kast WM. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PloS one. 2010; 5(5):e10471.
12. Chiriva-Internati M, Ferrari R, Prabhakar M, Yu Y, Baggoni L, Moreno J, Gagliano N, Portinaro N, Jenkins MR, Frezza EE, Hardwicke F, D'Cunha N, Kast W and Cobos E. The pituitary tumor transforming gene 1 (PTTG- 1): an immunological target for multiple myeloma. Journal of translational medicine. 2008; 6:15.
13. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S and Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. Journal of virology. 2008; 82(4):1968-1979.
14. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS and Dubinett SM. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Human gene therapy. 2000; 11(1):53-65.
15. Yasumoto K, Hanagiri T and Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. General thoracic and cardiovascular surgery. 2009; 57(9):449-457.
16. Raez LE, Fein S and Podack ER. Lung cancer immunotherapy. Clinical medicine & research. 2005; 3(4):221-228.
17. Wang J, Zou ZH, Xia HL, He JX, Zhong NS and Tao AL. Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PloS one. 2012; 7(3):e32695.
18. Sammut SJ, Feichtinger J, Stuart N, Wakeman JA, Larcombe L, McFarlane RJ. A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. Oncoscience. 2014; 1(5):349-359.
19. Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N and Kast WM. Sperm protein 17 is expressed in human somatic ciliated epithelia. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2004; 52(4):549-554.
20. Song JX, Cao WL, Li FQ, Shi LN and Jia X. Anti- Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells. Medical oncology (Northwood, London, England). 2012; 29(4):2923-2931.
21. Dadabayev AR, Wang Z, Zhang Y, Zhang J, Robinson WR and Lim SH. Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics? American journal of hematology. 2005; 80(1):6-11.
22. Li B, Zhu X, Sun L, Yuan L, Zhang J, Li H and Ye Z. Induction of a specific CD8+ T-cell response to cancer/ testis antigens by demethylating pre-treatment against osteosarcoma. Oncotarget. 2014.
23. Shan Q, Lou X, Xiao T, Zhang J, Sun H, Gao Y, Cheng S, Wu L, Xu N and Liu S. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer letters. 2013; 328(1):160-167.
24. Caballero OL, Shousha S, Zhao Q, Simpson AJG, Charles Coombes RC, Munro Neville A. Expression of Cancer/ Testis genes in ductal carcinoma in situ and benign lesions of the breast. Oncoscience 2014, 1(1):14-20.
25. Freitas M, Malheiros S, Stavale JN, Biassi TP, Zamuner FT, de Souza Begnami M, Soares FA and Vettore AL. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget. 2013; 4(4):636-646.
26. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan D, Pecorelli S, Parham GP and Cannon MJ. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. Journal of virology. 1999; 73(7):5402-5410.
27. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D and Lim SH. Successful generation of sperm protein 17 (Sp17)- specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17- positive multiple myeloma. Scandinavian journal of immunology. 2002; 56(4):429-433.
28. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B and Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002; 100(3):961-965.
29. Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL and Hermonat PL. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003; 102(9):3100-3107.
30. Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S and Mami-Chouaib F. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. International journal of cancer Journal international du cancer. 1998; 77(1):7-12.
31. Ortegel JW, Staren ED, Faber LP, Warren WH and Braun DP. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2002; 36(1):17-25.
32. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C and Busund LT. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011; 6(4):824-833.
33. Chen J, Hou J, Zhang J, An Y, Zhang X, Yue L, Liu J and Li X. Atorvastatin synergizes with IFN-gamma in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity. European journal of pharmacology. 2012; 682(1-3):161-170.
34. Dubinett S and Sharma S. Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment. Immunotherapy. 2009; 1(5):721-725.
35. Sautes-Fridman C, Dieu-Nosjean MC, Damotte D, Fisson S and Fridman WH. The immune microenvironments of lung and intraocular tumors. Bulletin du cancer. 2011; 98(6):58-61.